Corbus Pharmaceuticals (NASDAQ:CRBP – Get Free Report) and Madrigal Pharmaceuticals (NASDAQ:MDGL – Get Free Report) are both medical companies, but which is the better business? We will contrast the two companies based on the strength of their earnings, institutional ownership, risk, analyst recommendations, dividends, valuation and profitability.
Valuation and Earnings
This table compares Corbus Pharmaceuticals and Madrigal Pharmaceuticals”s gross revenue, earnings per share (EPS) and valuation.
| Gross Revenue | Price/Sales Ratio | Net Income | Earnings Per Share | Price/Earnings Ratio | |
| Corbus Pharmaceuticals | N/A | N/A | -$78.54 million | ($5.98) | -1.85 |
| Madrigal Pharmaceuticals | $958.40 million | 11.96 | -$288.28 million | ($12.80) | -38.83 |
Profitability
This table compares Corbus Pharmaceuticals and Madrigal Pharmaceuticals’ net margins, return on equity and return on assets.
| Net Margins | Return on Equity | Return on Assets | |
| Corbus Pharmaceuticals | N/A | -65.76% | -57.88% |
| Madrigal Pharmaceuticals | -27.32% | -50.15% | -25.44% |
Institutional & Insider Ownership
64.6% of Corbus Pharmaceuticals shares are held by institutional investors. Comparatively, 98.5% of Madrigal Pharmaceuticals shares are held by institutional investors. 3.5% of Corbus Pharmaceuticals shares are held by company insiders. Comparatively, 17.6% of Madrigal Pharmaceuticals shares are held by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock will outperform the market over the long term.
Analyst Ratings
This is a breakdown of current ratings and price targets for Corbus Pharmaceuticals and Madrigal Pharmaceuticals, as reported by MarketBeat.com.
| Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
| Corbus Pharmaceuticals | 2 | 0 | 7 | 2 | 2.82 |
| Madrigal Pharmaceuticals | 1 | 3 | 12 | 1 | 2.76 |
Corbus Pharmaceuticals presently has a consensus target price of $43.88, indicating a potential upside of 297.42%. Madrigal Pharmaceuticals has a consensus target price of $682.07, indicating a potential upside of 37.23%. Given Corbus Pharmaceuticals’ stronger consensus rating and higher possible upside, research analysts plainly believe Corbus Pharmaceuticals is more favorable than Madrigal Pharmaceuticals.
Risk and Volatility
Corbus Pharmaceuticals has a beta of 2.68, suggesting that its share price is 168% more volatile than the S&P 500. Comparatively, Madrigal Pharmaceuticals has a beta of -1.04, suggesting that its share price is 204% less volatile than the S&P 500.
Summary
Corbus Pharmaceuticals beats Madrigal Pharmaceuticals on 8 of the 14 factors compared between the two stocks.
About Corbus Pharmaceuticals
Corbus Pharmaceuticals Holdings, Inc., a biopharmaceutical company, develops products to defeat serious illness. It develops CRB-701, an antibody drug conjugate (ADC) that targets the expression of Nectin-4 on cancer cells to release a cytotoxic payload of monomethyl auristatin E (MMAE), which is in Phase I clinical trial; CRB-601, an anti-integrin monoclonal antibody that blocks the activation of TGFß expressed on cancer cells for the treatment of solid tumors; CRB-913, a peripherally restricted cannabinoid type-1 (CB1) receptor inverse agonist for the treatment of obesity. It has a licensing agreement with Jenrin Discovery, LLC to develop and commercialize the licensed products, including the Jenrin library of approximately 600 compounds, and multiple issued and pending patent filings. The company was incorporated in 2009 and is based in Norwood, Massachusetts.
About Madrigal Pharmaceuticals
Madrigal Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on the development of therapeutics for the treatment of non-alcoholic steatohepatitis (NASH) in the United States. Its lead product candidate is resmetirom, a liver-directed thyroid hormone receptor beta agonist, which is in Phase 3 clinical trials for treating NASH. The company is headquartered in West Conshohocken, Pennsylvania.
Receive News & Ratings for Corbus Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Corbus Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.
